Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
5697-56-3
Molecular formula
C34H50O7
Molecular weight
570.8 g/mol
Drug class
Licorice-derived triterpenoidanti-ulcer agent and 11β-hydroxysteroid dehydrogenase inhibitor
Mechanism of action
A glycyrrhetinic-acid derivative that inhibits 11β-hydroxysteroid dehydrogenase, reducing conversion of cortisol to cortisone in mineralocorticoid-sensitive tissues. Its gastroprotective actions have been attributed to increased mucosal resistance and effects on mucus secretion; the mechanism is not fully defined.
Indications / reported uses
Historically used for gastric and other digestive-tract ulcers in some countries; availability and authorised status are limited, and use can cause sodium retention, hypertension and hypokalaemia
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Carbenoxolone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Carbenoxolone Permitted Daily Exposure (PDE) report (the Carbenoxolone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Carbenoxolone Occupational Exposure Limit (OEL) report (the Carbenoxolone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.